The world's largest patient recruitment firm, Synexus Clinical
Research has bagged its first Hungarian company in a bid to exploit
the growing clinical trial opportunities in the emerging Eastern
Schering-Plough has announced plans to adopt a new global model to
standardise its clinical trial operations throughout the world -
aimed at improving trial consistencies, efficiencies and saving
Outsourcing-Pharma.com sheds some light on how pharma companies can
make sure they are choosing a contract research organisations (CRO)
that will stick to the rules of ethics when running clinical trials
in poorly-regulated countries...
Outsourcing-Pharma.com focus on: cutting the cost of clinical trials
After recent allegations in the media that poor and illiterate
patients in India are being used, often unknowingly, as human
guinea pigs to test new drugs for the pharma giants of the West,
Outsourcing-Pharma takes a look at how cutting...
Although clearing Parexel from contributing to the recent drug
trial disaster, a final UK Medicines and Healthcare products
Regulatory Agency (MHRA) report slammed the US firm for making a
number of basic errors during the trial process.
Kendle has seized a chance to expand and diversify its business,
snapping up the Phase II-IV Clinical Services unit of Charles River
Laboratories after it decided to get out of this area of clinical
trial services and focus instead...
As PRA International's profits tumble on the back of a major
contract loss, coupled with ongoing delays in its biotech
contracts, the company has introduced new project efficiency
measures and is focusing on increasing its international...
PPD managed a 42 per cent jump in pre-tax profit to the tune of
$63.8m (€50.1m) in the first quarter, fuelled by a strong growth in
new clinical trials business and helped by a milestone payment in
the discovery sciences segment.
PRA International has bought its first company in India - contract
research organisation (CRO) Sterling Synergy Systems - joining the
growing list of top CROs who have set up operations in this fertile
Covance has made a major expansion in its US Phase I/IIa drug
development capabilities, buying eight early-phase clinical
development sites from Radiant Research, who now plans to focus on
its Phase II-IV business.